Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Madrigal Pharmaceuticals Inc (MDGL) USD0.00010

Sell:$118.13 Buy:$118.29 Change: $0.29 (0.25%)
NASDAQ:2.26%
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Sell:$118.13
Buy:$118.29
Change: $0.29 (0.25%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Sell:$118.13
Buy:$118.29
Change: $0.29 (0.25%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Contact details

Address:
200 Barr Harbor Dr Ste 400
CONSHOHOCKEN
19428-2978
United States
Telephone:
+1 (404) 3809263
Website:
www.madrigalpharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MDGL
ISIN:
US5588681057
Market cap:
$1.82 billion
Shares in issue:
15.44 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Paul Friedman
    Chairman of the Board, Chief Executive Officer
  • Marc Schneebaum
    Chief Financial Officer, Senior Vice President
  • Rebecca Taub
    President of Research and Development, Chief Medical Officer, Director
  • Brian Lynch
    Senior Vice President, General Counsel
  • Remy Sukhija
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.